New applications of erythropoietin in cardiovascular disease: From haematopoiesis to cardiac protection;Nieuwe toepassingen van erytropoëtine bij cardiovasculaire aandoeningen: Van hematopoëse tot cardioprotectie

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 16, 2008, Pages 923-927

  Van Der Meer, P ^a   Van Veldhuisen, D J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; APOPTOSIS; BONE MARROW; CLINICAL TRIAL; DRUG EFFECT; EXERCISE TOLERANCE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART PROTECTION; HEMATOPOIESIS; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; PLEIOTROPY; REVIEW; VITAMIN DEFICIENCY;

ANEMIA; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS;

EID: 44949226913     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation. 2002;106:3068-72.
2. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-6.
3. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart. 2002;87:377-8.
4. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223-5.
5. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-9.
6. Meer P van der, Voors AA, Lipsic E, Smilde TDJ, Gilst WH van, Veldhuisen DJ van. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44:63-7.
7. Hillege HL, Girbes AR, Kam PJ de, Boomsma F, Zeeuw D de, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-10.
8. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-30.
9. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4:681-6.
10. Iversen PO, Woldbaek PR, Tønnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol. 2002;282:R166-72.
11. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45:391-9.
12. Meer P van der, Lipsic E, Westenbrink BD, Wal RM van de, Schoemaker RG, Vellenga E, et al. Levels of hematopoiesis inhibitor N-acetylseryl-aspartyl- lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743-7.
13. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-80.
14. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-9.
15. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096.e9-15.
16. Veldhuisen DJ van, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208-16.
17. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49:753-62.
18. Ghali JK, Anand I, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-35.
19. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
20. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84.
21. Veldhuisen DJ van, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. RED-HF Executive Committee. Eur J Heart Fail. 2007;9:110-2.
22. Meer P van der, Lipsic E, Henning RH, Boer RA de, Suurmeijer AJ, Veldhuisen DJ van, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail. 2004;6:853-9.
23. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg. 2005;130:877-8.
24. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641-7.
25. Lipsic E, Meer P van der, Henning RH, Suurmeijer AJ, Boddeus KM, Veldhuisen DJ van, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-9.
26. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
27. Meer P van der, Lipsic E, Henning RH, Boddeus K, Velden J van der, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-33.
28. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
29. Lipsic E, Meer P van der, Voors AA, Westenbrink BD, Heuvel AF van den, Boer HC de, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135-41.